SEC Comment Letter 0000000000-24-010159 to ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc.
Date: Sept. 9, 2024 · CIK: 0001859007 · Accession: 0000000000-24-010159
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281914
Letter
September 9, 2024 Stephen C. Glover Chief Executive Officer ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, FL 33326 Re:ZyVersa Therapeutics, Inc. Registration Statement on Form S-3 Filed September 3, 2024 File No. 333-281914 Dear Stephen C. Glover: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Faith Charles, Esq.
Show Raw Text
September 9, 2024
Stephen C. Glover
Chief Executive Officer
ZyVersa Therapeutics, Inc.
2200 N. Commerce Parkway, Suite 208
Weston, FL 33326
Re:ZyVersa Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 3, 2024
File No. 333-281914
Dear Stephen C. Glover:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Faith Charles, Esq.